Proteinuria in Children Infected with the Human Immunodeficiency Virus

Aida Chaparro, Charles D Mitchell, Carolyn Abitbol, James D. Wilkinson, Giovanna Baldarrago, Erika Lopez, Gaston E Zilleruelo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives: To determine the prevalence of proteinuria in a large cohort of children infected with the human immunodeficiency virus (HIV) and their longitudinal progression during treatment with highly active antiretroviral therapy. Study design: In a retrospective cohort study, 286 children infected with HIV were monitored with quantitative assays of proteinuria from January 1998 through January 2007, with monitoring of viral load, lymphocyte profiles, kidney function, and mortality rates. Proteinuria was quantitated by urine protein to creatinine ratio (Upr/cr). Results: Ninety-four (33%) had proteinuria at baseline. Of these, 32 (11.2%) had nephrotic range proteinuria (Upr/cr ≥ 1.0). Initial screening was at 11 ± 0.3 years of age, with an average follow-up of 5.6 ± 0.1 years. The mortality rate was significantly greater in those with proteinuria. During the period of observation, 15 patients with nephrotic proteinuria died or had development of end-stage renal disease, and 16 showed improvement. Of those with intermediate range proteinuria (Upr/cr ≥ 0.2 < 1.0), 3 progressed to nephrotic range proteinuria, and 39 (63%) showed resolution of the proteinuria (Upr/cr < 0.2). Improvement in proteinuria was correlated with decreasing viral load (r = 0.5; P < .01). Conclusions: Control of viral load with highly active antiretroviral therapy appears to prevent the progression of HIV-associated renal disease and improve survival rates in infected children.

Original languageEnglish
Pages (from-to)844-849
Number of pages6
JournalJournal of Pediatrics
Volume152
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Proteinuria
HIV
Creatinine
Viral Load
Urine
Highly Active Antiretroviral Therapy
Proteins
Kidney
Mortality
Chronic Kidney Failure
Cohort Studies
Survival Rate
Retrospective Studies
Observation
Lymphocytes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Proteinuria in Children Infected with the Human Immunodeficiency Virus. / Chaparro, Aida; Mitchell, Charles D; Abitbol, Carolyn; Wilkinson, James D.; Baldarrago, Giovanna; Lopez, Erika; Zilleruelo, Gaston E.

In: Journal of Pediatrics, Vol. 152, No. 6, 01.06.2008, p. 844-849.

Research output: Contribution to journalArticle

Chaparro, Aida ; Mitchell, Charles D ; Abitbol, Carolyn ; Wilkinson, James D. ; Baldarrago, Giovanna ; Lopez, Erika ; Zilleruelo, Gaston E. / Proteinuria in Children Infected with the Human Immunodeficiency Virus. In: Journal of Pediatrics. 2008 ; Vol. 152, No. 6. pp. 844-849.
@article{70afaf5358284165baaa1eec2b6032b3,
title = "Proteinuria in Children Infected with the Human Immunodeficiency Virus",
abstract = "Objectives: To determine the prevalence of proteinuria in a large cohort of children infected with the human immunodeficiency virus (HIV) and their longitudinal progression during treatment with highly active antiretroviral therapy. Study design: In a retrospective cohort study, 286 children infected with HIV were monitored with quantitative assays of proteinuria from January 1998 through January 2007, with monitoring of viral load, lymphocyte profiles, kidney function, and mortality rates. Proteinuria was quantitated by urine protein to creatinine ratio (Upr/cr). Results: Ninety-four (33{\%}) had proteinuria at baseline. Of these, 32 (11.2{\%}) had nephrotic range proteinuria (Upr/cr ≥ 1.0). Initial screening was at 11 ± 0.3 years of age, with an average follow-up of 5.6 ± 0.1 years. The mortality rate was significantly greater in those with proteinuria. During the period of observation, 15 patients with nephrotic proteinuria died or had development of end-stage renal disease, and 16 showed improvement. Of those with intermediate range proteinuria (Upr/cr ≥ 0.2 < 1.0), 3 progressed to nephrotic range proteinuria, and 39 (63{\%}) showed resolution of the proteinuria (Upr/cr < 0.2). Improvement in proteinuria was correlated with decreasing viral load (r = 0.5; P < .01). Conclusions: Control of viral load with highly active antiretroviral therapy appears to prevent the progression of HIV-associated renal disease and improve survival rates in infected children.",
author = "Aida Chaparro and Mitchell, {Charles D} and Carolyn Abitbol and Wilkinson, {James D.} and Giovanna Baldarrago and Erika Lopez and Zilleruelo, {Gaston E}",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.jpeds.2007.11.007",
language = "English",
volume = "152",
pages = "844--849",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Proteinuria in Children Infected with the Human Immunodeficiency Virus

AU - Chaparro, Aida

AU - Mitchell, Charles D

AU - Abitbol, Carolyn

AU - Wilkinson, James D.

AU - Baldarrago, Giovanna

AU - Lopez, Erika

AU - Zilleruelo, Gaston E

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Objectives: To determine the prevalence of proteinuria in a large cohort of children infected with the human immunodeficiency virus (HIV) and their longitudinal progression during treatment with highly active antiretroviral therapy. Study design: In a retrospective cohort study, 286 children infected with HIV were monitored with quantitative assays of proteinuria from January 1998 through January 2007, with monitoring of viral load, lymphocyte profiles, kidney function, and mortality rates. Proteinuria was quantitated by urine protein to creatinine ratio (Upr/cr). Results: Ninety-four (33%) had proteinuria at baseline. Of these, 32 (11.2%) had nephrotic range proteinuria (Upr/cr ≥ 1.0). Initial screening was at 11 ± 0.3 years of age, with an average follow-up of 5.6 ± 0.1 years. The mortality rate was significantly greater in those with proteinuria. During the period of observation, 15 patients with nephrotic proteinuria died or had development of end-stage renal disease, and 16 showed improvement. Of those with intermediate range proteinuria (Upr/cr ≥ 0.2 < 1.0), 3 progressed to nephrotic range proteinuria, and 39 (63%) showed resolution of the proteinuria (Upr/cr < 0.2). Improvement in proteinuria was correlated with decreasing viral load (r = 0.5; P < .01). Conclusions: Control of viral load with highly active antiretroviral therapy appears to prevent the progression of HIV-associated renal disease and improve survival rates in infected children.

AB - Objectives: To determine the prevalence of proteinuria in a large cohort of children infected with the human immunodeficiency virus (HIV) and their longitudinal progression during treatment with highly active antiretroviral therapy. Study design: In a retrospective cohort study, 286 children infected with HIV were monitored with quantitative assays of proteinuria from January 1998 through January 2007, with monitoring of viral load, lymphocyte profiles, kidney function, and mortality rates. Proteinuria was quantitated by urine protein to creatinine ratio (Upr/cr). Results: Ninety-four (33%) had proteinuria at baseline. Of these, 32 (11.2%) had nephrotic range proteinuria (Upr/cr ≥ 1.0). Initial screening was at 11 ± 0.3 years of age, with an average follow-up of 5.6 ± 0.1 years. The mortality rate was significantly greater in those with proteinuria. During the period of observation, 15 patients with nephrotic proteinuria died or had development of end-stage renal disease, and 16 showed improvement. Of those with intermediate range proteinuria (Upr/cr ≥ 0.2 < 1.0), 3 progressed to nephrotic range proteinuria, and 39 (63%) showed resolution of the proteinuria (Upr/cr < 0.2). Improvement in proteinuria was correlated with decreasing viral load (r = 0.5; P < .01). Conclusions: Control of viral load with highly active antiretroviral therapy appears to prevent the progression of HIV-associated renal disease and improve survival rates in infected children.

UR - http://www.scopus.com/inward/record.url?scp=43549102233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549102233&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2007.11.007

DO - 10.1016/j.jpeds.2007.11.007

M3 - Article

C2 - 18492529

AN - SCOPUS:43549102233

VL - 152

SP - 844

EP - 849

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -